Latest research on Quetiapine

Quetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also has an antagonistic effect on the histamine H1 receptor.

Quetiapine dosage

Seventy-five patients were taking atypical antipsychotics (Risperidone, Paliperidone, Clozapine, Aripiprazole, Ziprasidone, and/or Quetiapine) at a median Chlorpromazine equivalent dose of 349.20 (277.64) mg/day. [source, 2016]
Additionally, sub-analysis of the 50, 150, and 300 mg/day of Quetiapine was performed to examine whether the dose affected its efficacy, acceptability, and tolerability. [source, 2016]
The extracted data collected from each clinical trial consisted of the following: 1) important information applied for quality assessments; 2) basic characteristics data regarding population, diagnostic criteria, study designs, and eligibility/ineligibility criteria; 3) forms, doses, and treatment duration of Quetiapine versus placebo; 4) interesting outcomes; and 5) intention-to-treat results. [source, 2016]
To determine whether dose affected efficacy, the pooled analysis of the 50, 150, and 300 mg Quetiapine may occur. [source, 2016]
The dose of Quetiapine ranged from 50 to 300 mg/day (Table 1). [source, 2016]
This meta-analysis suggests that low dose of Quetiapine as well as SSRIs are efficacious in the treatment of adult patients with GAD which was similar to previous studies in the treatment of GAD with antidepressants, such as SSRIs and the SNRIs. [source, 2016]
In this meta-analysis, the acceptability of Quetiapine at all doses in GAD treatment was less than that of the placebo. [source, 2016]
Similarly, the tolerability of Quetiapine at all doses in GAD treatment was found to be less than that of the placebo which is comparable with antidepressants, including SSRIs and SNRIs in the treatment of GAD patients. [source, 2016]
Unfortunately, only tolerability of low dose Quetiapine in the present meta-analysis was comparable to SSRIs. [source, 2016]
The relative low acceptability and tolerability of higher dose Quetiapine may be caused by its adverse events. [source, 2016]